LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

BioCryst Pharmaceuticals Inc

Închisă

SectorSănătate

8.28 -0.24

Rezumat

Modificarea prețului

24h

Curent

Minim

8.27

Maxim

8.46

Indicatori cheie

By Trading Economics

Venit

5.1M

5.1M

Vânzări

18M

163M

Marjă de profit

3.113

Angajați

580

EBITDA

-84M

-62M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+110.59% upside

Dividende

By Dow Jones

Următoarele câștiguri

3 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-88M

1.7B

Deschiderea anterioară

8.52

Închiderea anterioară

8.28

Sentimentul știrilor

By Acuity

32%

68%

94 / 371 Clasament în Healthcare

BioCryst Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 sept. 2025, 23:07 UTC

Achiziții, Fuziuni, Preluări

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

2 sept. 2025, 22:10 UTC

Principalele dinamici ale pieței

Bruker Shares Fall on Convertible Share Offering Aimed at Debt Repayment

2 sept. 2025, 21:47 UTC

Câștiguri

Alimentation Couche-Tard Logs Lower Profit, Revenue in 1Q

2 sept. 2025, 16:52 UTC

Principalele dinamici ale pieței

CleanCore Solutions Shares Drop After $175 Million Private Investment

2 sept. 2025, 22:47 UTC

Market Talk

Google, Apple Can Grow AI Deal With Lawsuit Resolved -- Market Talk

2 sept. 2025, 21:40 UTC

Achiziții, Fuziuni, Preluări

Investors Have to Be Ready for State Capitalism. What Areas to Watch. -- Barrons.com

2 sept. 2025, 21:07 UTC

Câștiguri

Couche-Tard 1Q U.S. Same-Store Merchandise Revenue Up 0.4% >ATD.T

2 sept. 2025, 21:07 UTC

Câștiguri

Couche-Tard 1Q Canada Same-Store Merchandise Revenue Up 4.1% >ATD.T

2 sept. 2025, 21:05 UTC

Câștiguri

Couche-Tard 1Q Rev $17.35B >ATD.T

2 sept. 2025, 21:05 UTC

Câștiguri

Couche-Tard 1Q Adj EPS 78c >ATD.T

2 sept. 2025, 21:05 UTC

Câștiguri

Couche-Tard 1Q EPS 82c >ATD.T

2 sept. 2025, 21:05 UTC

Câștiguri

Couche-Tard 1Q Net $782.5M >ATD.T

2 sept. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

2 sept. 2025, 20:53 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Knight-Swift Transportation Endorses Union Pacific, Norfolk Southern Merger -- Market Talk

2 sept. 2025, 20:51 UTC

Achiziții, Fuziuni, Preluări

Buffett Dislikes Breakup of Kraft Heinz. It's Been One of His Worst Investments. -- Barrons.com

2 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 sept. 2025, 20:27 UTC

Câștiguri

NIO Stock Rises After Second-Quarter Loss Narrows -- Barrons.com

2 sept. 2025, 20:24 UTC

Achiziții, Fuziuni, Preluări

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

2 sept. 2025, 20:18 UTC

Achiziții, Fuziuni, Preluări

Procter & Gamble Does Not Endorse Tutanota's Unsolicited Mini-Tender Offer >PG

2 sept. 2025, 20:17 UTC

Achiziții, Fuziuni, Preluări

Procter & Gamble: Tutanota Says It Expects to Extend Offer for Successive Periods of Up to 180 Days Until Market Price Exceeds Offer Price >PG

2 sept. 2025, 20:16 UTC

Achiziții, Fuziuni, Preluări

Procter & Gamble: 'Shareholders Who Tender Their Shrs in the Offer Will Receive a Below-Market Price' >PG

2 sept. 2025, 20:16 UTC

Achiziții, Fuziuni, Preluări

Procter & Gamble: Offer by Tutanota Is to Purchase Up to 500,000 Shrs at $128 Each

2 sept. 2025, 20:15 UTC

Achiziții, Fuziuni, Preluări

Procter & Gamble Has Been Notified of Unsolicited Mini-Tender Offer by Tutanota >PG

2 sept. 2025, 19:55 UTC

Câștiguri

GM Had a Record Month of EV Sales. A 'Collapse' Is Coming. -- Barrons.com

2 sept. 2025, 19:50 UTC

Achiziții, Fuziuni, Preluări

Food Giants Are Struggling. Could Mergers, Spinoffs, and Activist Stakes Help? -- Barrons.com

2 sept. 2025, 19:09 UTC

Market Talk

Oil Futures Gain on Geopolitical Premium -- Market Talk

2 sept. 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Recover $3 Level -- Market Talk

2 sept. 2025, 18:12 UTC

Market Talk

Gold Pushes To New Record -- Market Talk

2 sept. 2025, 17:04 UTC

Market Talk

Philip Morris Riding Smoke-Free Products to Higher Margins -- Market Talk

2 sept. 2025, 16:57 UTC

Achiziții, Fuziuni, Preluări

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

Comparație

Modificare preț

BioCryst Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

110.59% sus

Prognoză pe 12 luni

Medie 17.5 USD  110.59%

Maxim 30 USD

Minim 12 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBioCryst Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

6

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

94 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.